Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation

Y.T. Wachtfogel, C.E. Hack, J.H Nuijens, C. Kettner, T.M. Reilly, R.M. Knabb, Rainer Bischoff, H. Tschesche, H. Wenzel, U. Kucich

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Scopus)

Abstract

Cardiopulmonary bypass causes hemorrhagic complications and initiates a biochemical and cellular "whole body inflammatory response." This study investigates whether a variety of selective inhibitors of the contact pathway of intrinsic coagulation modulate complement and neutrophil activation during simulated extracorporeal circulation. After 60 min of recirculation in the presence of the slow tight-binding boronic acid inhibitor, Bz-Pro-Phe-boroArg-OH (10.7 microM), complete inhibition of kallikrein-C1-inhibitor complex formation and marked inhibition of C1-C1-inhibitor complex formation and the release of human neutrophil elastase were observed. Arg15-aprotinin (3.1 microM), Ala357,Arg358 alpha 1-antitrypsin (2.6 microM), and soybean trypsin inhibitor (48.0 microM) either completely or partially inhibited the generation of kallikrein-C1-inhibitor complexes but were less effective inhibitors of human neutrophil elastase release. The second-order rate constants for the inhibition of kallikrein in purified systems are consistent with the order of effectiveness of the inhibitors in blocking human neutrophil elastase release in heparinized blood. Our results suggest that low-molecular-weight selective inhibitors of kallikrein may be effective agents in the attenuation of the contact-mediated inflammatory response in cardiopulmonary bypass
Original languageDutch
Pages (from-to)H1352 - H1357
JournalAm.J.Physiol
Volume268
Issue number3 Pt 2
Publication statusPublished - 1995

Cite this